Hi all,
I do not have a licence for stata to combine the imputations for amelia. I have thought about using an aggregate function in SPSS to generate means and standard deviations for cases across all the five files (My gut instinct is that this is way too simple). I have also thought about using NORM to combine the five file parameters (Again seems to simple). Any advice on how to combine the amelia data files without stata would be much appreciated.
Kind regards Paul
----04735509266822180
Sender: owner-amelia(a)latte.harvard.edu
Precedence: bulk
X-MajorDomo: amelia
SUP.ER st.ock pick for you Tod.ay_!_!_! OUR last sto.ck pick AMUC is up 300% for the la.st 10 days
from $1 to $3
CSJJ - CSJJ in Nego.tiations to Acquire 35% in BioMed.icom Inc - stock is s.et to go cra.zy on
Tuesday af.ter the announc.ement on Friday..
!!!!! CSJJ is up 50% on Mon.day.. !!! !!!!! CSJJ is up 50% on M.onday.. !!!
CSJJ - This is sto.ck G.EM.. its great buy below 10-14 cents and huge pro.fits could be made with
CSJJ because it is lower priced stock so it can go up not only a few percent but a few hundred or
thousand %.
B.REAKING N.EWS -> JU.MP ON BOAR.D TO.DAY + HU.GE PROF.ITS EXP.ECTED
CSJJ in Negotiations to Acquire 35% in BioMedicom Inc
***********************************************************************
Congratulations to all members who took advantage of our last pick
AMUC - The stock was prof.iled at $1 and hit $3.20
***********************************************************************
We believe that the SPE.CULATIVE NEAR T.ERM TARGET PR.ICE for next 3 days - $0.12
We believe that the SPECULATI.VE NEAR TERM TA.RGET PRI.CE for next 5 days - $0.19
>>>>>>>>> CSJJ CSJJ CSJJ CSJJ CSJJ <<<<<<<<<<<
Tr.ading Ale.rt
Coastal Holdings, Inc.
Symbol: SCJJ
Current Price: $0.032
We believe that the SPECULA.TIVE NEAR TERM T.ARGET PRICE for n.ext 3 days - $0.12
We bel.ieve that the SPECU.LATIVE NEAR T.ERM T.ARGET PRICE for next 5 days - $0.19
NEWS * NEWS * NEWS * NEWS * NEWS
----------------------------------------------------------------
Coastal Holdings, Inc. in Negotiations to Acquire Interest in BioMedicom Inc.
----------------------------------------------------------------
HOUSTON , Jun 25, 2004 (PRIMEZONE via COMTEX) -- Coastal Holdings, Inc. (Pink Sheets:CSJJ) is pleased to announce that it is in negotiations to acquire a 35%-45% equity interest in BioMedicom Inc. (BIOMED). BIOMED will be an exhibitor at the International Congress of Radiology to be held June 27-29, 2004 at the Palais des Congres de Montreal. CSJJ CEO Andrea Cortellazzi will be in negotiations with BIOMED CEO Michael Berman prior to the start of the Congress in Montreal. CSJJ will announce the outcome of this meeting at a future date. The investment in BIOMED will be for a total of $2M with an initial deposit of $300,000 upon contract signing. As part of the investment, CSJJ would receive distribution rights in North America to SONOReal, a revolutionary add-on to any ultrasound system. This product makes 3D ultrasound imaging easy to learn, use and afford. It increases the productive life of an existing ultrasound system, enabling 3D visualization in real-time, while maintaining familiar protocols. SONOReal has received several regulatory clearances, notably from the ISO and the FDA.
About BioMedicom Inc. (BIOMED)
---------------
Disclaimer
---------------
Information within this email contains "forward looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21B of the Securities Exchange Act of 1934. Any statements that express or involve discussions with respect to predictions, goals, expectations, beliefs, plans, projections, objectives, assumptions or future events or performance are not statements of historical fact and may be "forward looking statements."
Forward looking statements are based on expectations, estimates and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements in this action may be identified through the use of words such as: "projects", "foresee", "expects", "estimates," "believes," "understands" "will," "part of: "anticipates," or that by statements indicating certain actions "may," "could," or "might" occur. All information provided within this email pertaining to investing, stocks, securities must be understood as information provided and not investment advice. we advise all readers and subscribers to seek advice from a registered professional securities representative before deciding to trade in stocks featured within this email. None of the material within this report shall be construed as any kind of investment advice. Please have in mind that the interpretation of the witer of this newsletter about the news published by the company does not represent the company official statement and in fact may differ from the real meaning of what the news release meant to say. Please read the news release by yourself and judge by yourself about the details in it.
In compliance with Section 17(b), we disclose the holding of CSJJ shares prior to the publication of this report. Be aware of an inherent conflict of interest resulting from such holdings due to our intent to profit from the liquidation of these shares. Shares may be sold at any time, even after positive statements have been made regarding the above company. Since we own shares, there is an inherent conflict of interest in our statements and opinions. Readers of this publication are cautioned not to place undue reliance on forward-looking statements, which are based on certain assumptions and expectations involving various risks and uncertainties, that could cause results to differ materially from those set forth in the forward- looking statements.
Please be advised that nothing within this email shall constitute a solicitation or an offer to buy or sell any security mentioned herein. This newsletter is neither a registered investment advisor nor affiliated with any broker or dealer. All statements made are our express opinion only and should be treated as such. We may own, buy and sell any securities mentioned at any time. This report includes forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. These statements may include terms as "expect", "believe", "may", "will", "move","undervalued" and "intend" or similar terms. This newsletter was paid $5500 from third party to send this report. PLEASE DO YOUR OWN DUE DILIGENCE BEFORE INVESTING IN ANY PROFILED COMPANY. You may lose money from investing in Penny Stocks.
----04735509266822180--
----3040328318787280
Sender: owner-amelia(a)latte.harvard.edu
Precedence: bulk
X-MajorDomo: amelia
SUPER st.ock pick for you on Monday!-!-! OUR last st.ock pick AMUC is up 300% for the last 10 days
from $1 to $3
CSJJ - CSJJ in Nego.tiations to Acquire 35% in BioMedicom Inc - st.ock is set to go crazy on
Monday after the announcement on Friday..
CSJJ - This is st.ock GEM.. its a great buy below 10-14 cents and huge profits could be made with
CSJJ because it is lower priced stock so it can go up not only a few per%cent but a few hundred or
thousand %.
BREAKING NEWS -> JUMP ON-BOARD TODAY... + HUGE PRO.FITS EXPECTED
CSJJ in Nego.tiations to Acquire 35% in BioMedicom Inc
***********************************************************************
Congratula.tions to all members who took advantage of our last pick
AMUC - The stock was profiled at $1 and hit $3.20
***********************************************************************
We believe that the SPEC.ULATIVE NEAR TERM TARGET PRICE for next 3 days - $0.11
We believe that the SPECU-LATIVE NEAR TERM TARGET PRICE for next 5 days - $0.17
>>>>>>>>> CSJJ CSJJ CSJJ CSJJ CSJJ <<<<<<<<<<<
Trading Alert
Coastal Holdings, Inc.
Symbol: SCJJ
Current Price: $0.021
We believe that the SPECULATIVE NEAR TERM TARGET PRICE for next 3 days - $0.11
We believe that the SPECULATIVE NEAR TERM TARGET PRICE for next 5 days - $0.15
NEWS-* NEWS *_NEWS_* NEWS *-NEWS
----------------------------------------------------------------
Coastal Holdings, Inc. in Negotiations to Acquire Interest in BioMedicom Inc.
----------------------------------------------------------------
HOUSTON , Jun 25, 2004 (PRIMEZONE via COMTEX) -- Coastal Holdings, Inc. (Pink Sheets:CSJJ) is pleased to announce that it is in negotiations to acquire a 35%-45% equity interest in BioMedicom Inc. (BIOMED). BIOMED will be an exhibitor at the International Congress of Radiology to be held June 27-29, 2004 at the Palais des Congres de Montreal. CSJJ CEO Andrea Cortellazzi will be in negotiations with BIOMED CEO Michael Berman prior to the start of the Congress in Montreal. CSJJ will announce the outcome of this meeting at a future date. The investment in BIOMED will be for a total of $2M with an initial deposit of $300,000 upon contract signing. As part of the investment, CSJJ would receive distribution rights in North America to SONOReal, a revolutionary add-on to any ultrasound system. This product makes 3D ultrasound imaging easy to learn, use and afford. It increases the productive life of an existing ultrasound system, enabling 3D visualization in real-time, while maintaining familiar protocols. SONOReal has received several regulatory clearances, notably from the ISO and the FDA.
About BioMedicom Inc. (BIOMED)
---------------
Disclaimer
---------------
Information within this email contains "forward looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21B of the Securities Exchange Act of 1934. Any statements that express or involve discussions with respect to predictions, goals, expectations, beliefs, plans, projections, objectives, assumptions or future events or performance are not statements of historical fact and may be "forward looking statements."
Forward looking statements are based on expectations, estimates and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements in this action may be identified through the use of words such as: "projects", "foresee", "expects", "estimates," "believes," "understands" "will," "part of: "anticipates," or that by statements indicating certain actions "may," "could," or "might" occur. All information provided within this email pertaining to investing, stocks, securities must be understood as information provided and not investment advice. we advise all readers and subscribers to seek advice from a registered professional securities representative before deciding to trade in stocks featured within this email. None of the material within this report shall be construed as any kind of investment advice. Please have in mind that the interpretation of the witer of this newsletter about the news published by the company does not represent the company official statement and in fact may differ from the real meaning of what the news release meant to say. Please read the news release by yourself and judge by yourself about the details in it.
In compliance with Section 17(b), we disclose the holding of CRHI shares prior to the publication of this report. Be aware of an inherent conflict of interest resulting from such holdings due to our intent to profit from the liquidation of these shares. Shares may be sold at any time, even after positive statements have been made regarding the above company. Since we own shares, there is an inherent conflict of interest in our statements and opinions. Readers of this publication are cautioned not to place undue reliance on forward-looking statements, which are based on certain assumptions and expectations involving various risks and uncertainties, that could cause results to differ materially from those set forth in the forward- looking statements.
Please be advised that nothing within this email shall constitute a solicitation or an offer to buy or sell any security mentioned herein. This newsletter is neither a registered investment advisor nor affiliated with any broker or dealer. All statements made are our express opinion only and should be treated as such. We may own, buy and sell any securities mentioned at any time. This report includes forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. These statements may include terms as "expect", "believe", "may", "will", "move","undervalued" and "intend" or similar terms. This newsletter was paid $16500 from third party to send this report. PLEASE DO YOUR OWN DUE DILIGENCE BEFORE INVESTING IN ANY PROFILED COMPANY. You may lose money from investing in Penny Stocks.
----3040328318787280--
----8397922528519859
Sender: owner-amelia(a)latte.harvard.edu
Precedence: bulk
X-MajorDomo: amelia
UPTD.. This St.ock is going Nu.ts - UPTD just an.nounced e.xciting news..
+++ HO.T Tradi.ng Al.ert +++ HO.T Trad.ing Alert ++++
STRONG BUY! UPTD cur.rently tra.ding at $0.91 and is headed to $2.10
Company Profile:
UPTREND Corp
Symbol: UPTD
Current Price: $0.91
Rating: Undervalued
Recommenda.tion: STRONG BUY
We Believe the SPECULATIVE NEAR TERM TARGET PRICE is - $2.40
We Believe the SPECULATIVE LONG TERM TARGET PRICE - $2.82
UPTD * UPTD * UPTD * UPTD * UPTD
UPTD is real company producing and distributing very HOT product - The "AirVest" is
the most revoluti.onary prod.uct to hit the motorsports industry since the helmet. An
innovation in high quality safety gear the AirVest acts as a wearable airbag in the
event of an accident, helping to protect the rider's chest and back from impact.
AirVest is light weight, inflates in milliseconds and is reusable JUST IMAGINE OF THE
DEMAND FOR SUCH PRODUCT!!!
Breaking News for UPTD: UPTREND Receives Initial Order
Breaking News for UPTD: UPTREND Corp. Featured on WallStreetReporter
Company Profile:
UPTREND Corp
Symbol: UPTD
Current Price: $0.91
Rating: Undervalued
Recommendation: STRONG BUY
We Believe the SPECULATIVE NEAR TERM TARGET PRICE is - $2.40
We Believe the SPECULATIVE LONG TERM TARGET PRICE - $2.82
** This is REAL company with real products and its stock is headed up ****
--------->>> NEWS <<<-------------------
AUSTIN, Texas, Jun 22, 2004 (BUSINESS WIRE) -- UPTREND Corp. (Pink Sheets:UPTD) announced today that Robert Bitterli, CEO of UPTREND Corp., was featured in an interview by Wall Street Reporter.
Mr. Bitterli discussed the impact and opportunities UPTREND'S patented AirVest product will have on the motorsports industry and the Company's direct sales and marketing strategy.
The "AirVest" is the most revolutionary product to hit the motorsports industry since the helmet. An innovation in high-quality safety gear, the AirVest acts as a wearable airbag in the event of an accident, helping to protect the rider's chest and back from impact. AirVest is lightweight, inflates in milliseconds and is reusable.
---------------
Disclaimer
---------------
Information within this email contains "forward looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21B of the Securities Exchange Act of 1934. Any statements that express or involve discussions with respect to predictions, goals, expectations, beliefs, plans, projections, objectives, assumptions or future events or performance are not statements of historical fact and may be "forward looking statements."
Forward looking statements are based on expectations, estimates and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements in this action may be identified through the use of words such as: "projects", "foresee", "expects", "estimates," "believes," "understands" "will," "part of: "anticipates," or that by statements indicating certain actions "may," "could," or "might" occur. All information provided within this email pertaining to investing, stocks, securities must be understood as information provided and not investment advice. we advise all readers and subscribers to seek advice from a registered professional securities representative before deciding to trade in stocks featured within this email. None of the material within this report shall be construed as any kind of investment advice. Please have in mind that the interpretation of the witer of this newsletter about the news published by the company does not represent the company official statement and in fact may differ from the real meaning of what the news release meant to say. Please read the news release by yourself and judge by yourself about the details in it.
In compliance with Section 17(b), we disclose the holding of UPTD shares prior to the publication of this report. Be aware of an inherent conflict of interest resulting from such holdings due to our intent to profit from the liquidation of these shares. Shares may be sold at any time, even after positive statements have been made regarding the above company. Since we own shares, there is an inherent conflict of interest in our statements and opinions. Readers of this publication are cautioned not to place undue reliance on forward-looking statements, which are based on certain assumptions and expectations involving various risks and uncertainties, that could cause results to differ materially from those set forth in the forward- looking statements.
Please be advised that nothing within this email shall constitute a solicitation or an offer to buy or sell any security mentioned herein. This newsletter is neither a registered investment advisor nor affiliated with any broker or dealer. All statements made are our express opinion only and should be treated as such. We may own, buy and sell any securities mentioned at any time. This report includes forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. These statements may include terms as "expect", "believe", "may", "will", "move","undervalued" and "intend" or similar terms. This newsletter was paid $12500 from third party to send this report. PLEASE DO YOUR OWN DUE DILIGENCE BEFORE INVESTING IN ANY PROFILED COMPANY. You may lose money from investing in Penny Stocks.
---------------------
----8397922528519859--
----091014730018836
Sender: owner-amelia(a)latte.harvard.edu
Precedence: bulk
X-MajorDomo: amelia
SUPER stock pick for you Today!!!
CRHI - This is stock GEM.. it is trading at 10-12 cents range and
its expected that after the news they released and big PR campaign the stock
goes to 20-30 cents very easily.. Jump on board today!!!
BREAKING NEWS -> JUMP ON BOARD TODAY + HUGE PROFITS EXPECTED
***********************************************************************
Congratulations to all members who took advantage of our last pick
PAYD - The stock was profiled at 20 cents and hit $0.80
***********************************************************************
We believe that the SPECULATIVE NEAR TERM TARGET PRICE for next 3 days - $0.29
We believe that the SPECULATIVE NEAR TERM TARGET PRICE for next 5 days - $0.38
CRHI is our top pick for the third week of June!!!!
>>>>>>>>> CRHI CRHI CRHI CRHI CRHI CRHI <<<<<<<<<<<
++ Trading Alert ++
Company Profile
Communications Research, Inc
Symbol: CRHI
Current Price: $0.10
We believe that the SPECULATIVE NEAR TERM TARGET PRICE for next 3 days - $0.29
We believe that the SPECULATIVE NEAR TERM TARGET PRICE for next 5 days - $0.38
NEWS * NEWS * NEWS * NEWS * NEWS
----------------------------------------------------------------
Communications Research Secures Financing for Kickoff of TeleWRITER Software Sales and Marketing
----------------------------------------------------------------
Reasons to own CRHI
TeleWRITER has not been upgraded for over 5 years but nonetheless still commands a very loyal following. Communications Research acquired the software 2 years ago and will have its upgrade completed just in time for InfoComm. Beta testing will begin almost immediately and sales are expected to kick off in October. TeleWRITER sales will add considerably and immediately to the company's bottom line. CRHI's Systems Integration division is also performing above expectations and they have recently hired a number of contract employees to assist the company on fulfillment.
InfoComm is a key industry event and provides the perfect platform for the company to springboard its TeleWRITER 3.0 upgrade. It is the nation's largest business-to-business industry tradeshow for pro-AV communications systems.
At its peak, TeleWRITER-AGS had approximately a 60% share of the collaborative computing market in the mid-1990's, but the prior owners failed to fully maintain product due to private personal circumstances. CRHI acquired the technology and is near completion of the upgrades necessary to make the product operational with virtually all current software platforms. The market has exceeded industry expectations over the years and currently has well over $3 billion in annual revenues and growing.
-------------------READ READ READ----------------------
Communications Research Secures Financing for Kickoff of TeleWRITER Software Sales and Marketing
-------------------------------------------------------
MAHWAH, N.J., Jun 04, 2004 (PRIMEZONE via COMTEX) -- Communications Research, Inc. (CRHI) announced that it has secured financing for the sales and marketing re-launch of TeleWRITER 3.0 and has commitments for additional funding to aggressively position TeleWRITER as a key industry player in the $3 billion collaborative computing market.
"This major step puts the final piece of the puzzle in place for the re-launch of TeleWRITER, which promises to be a multi-million dollar product for the company within 12 months," remarked company president Carl Ceragno. "Beta-testing with major power users will begin in the next two weeks and we have been taken aback by the strong response we've received from current users clamoring for the upgrade. This is a very exciting time for the company."
At its peak, TeleWRITER-AGS had approximately a 60% share of the collaborative computing market in the mid-1990s. CRHI acquired the technology 4 years ago, with the expectation of re-launching the product to old users and capturing the rapidly growing market. Early indications suggest that there is still considerable interest from prior users and new prospective users are enthusiastic about TeleWRITERS' features and price-point.
---------------
Disclaimer
---------------
Information within this email contains "forward looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21B of the Securities Exchange Act of 1934. Any statements that express or involve discussions with respect to predictions, goals, expectations, beliefs, plans, projections, objectives, assumptions or future events or performance are not statements of historical fact and may be "forward looking statements."
Forward looking statements are based on expectations, estimates and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements in this action may be identified through the use of words such as: "projects", "foresee", "expects", "estimates," "believes," "understands" "will," "part of: "anticipates," or that by statements indicating certain actions "may," "could," or "might" occur. All information provided within this email pertaining to investing, stocks, securities must be understood as information provided and not investment advice. we advise all readers and subscribers to seek advice from a registered professional securities representative before deciding to trade in stocks featured within this email. None of the material within this report shall be construed as any kind of investment advice. Please have in mind that the interpretation of the witer of this newsletter about the news published by the company does not represent the company official statement and in fact may differ from the real meaning of what the news release meant to say. Please read the news release by yourself and judge by yourself about the details in it.
In compliance with Section 17(b), we disclose the holding of CSRZ shares prior to the publication of this report. Be aware of an inherent conflict of interest resulting from such holdings due to our intent to profit from the liquidation of these shares. Shares may be sold at any time, even after positive statements have been made regarding the above company. Since we own shares, there is an inherent conflict of interest in our statements and opinions. Readers of this publication are cautioned not to place undue reliance on forward-looking statements, which are based on certain assumptions and expectations involving various risks and uncertainties, that could cause results to differ materially from those set forth in the forward- looking statements.
Please be advised that nothing within this email shall constitute a solicitation or an offer to buy or sell any security mentioned herein. This newsletter is neither a registered investment advisor nor affiliated with any broker or dealer. All statements made are our express opinion only and should be treated as such. We may own, buy and sell any securities mentioned at any time. This report includes forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. These statements may include terms as "expect", "believe", "may", "will", "move","undervalued" and "intend" or similar terms. This newsletter was paid $16500 from third party to send this report. PLEASE DO YOUR OWN DUE DILIGENCE BEFORE INVESTING IN ANY PROFILED COMPANY. You may lose money from investing in Penny Stocks.
----091014730018836--
The page referred states that:
"If there are only a few out of bounds predictions, a reasonable strategy is to round the imputations below zero up to zero and likewise those above one down to one."
Is there a practical threshold guideline, perhaps a percentage of observations, that constitutes "a few"?
And does this advice hold for any out of bounds predictions, irrespective of the magnitude of distance from the bound? If not, are there practical guidelines for determining when even a few observations are so far out of bounds that the corrective measures are required.
Thanks in advance.
----- Original Message -----
From: Gary King <king(a)harvard.edu>
Date: Monday, June 7, 2004 5:00 pm
Subject: Re: [amelia] impossible values
>
> Usually if you transform the data before Amelia, impute, and then
> transform back, you can avoid this problem. See
> http://gking.harvard.edu/amelia/node22.html for more details about
> thisand other procedures in more complicated situations.
> Best of luck,
> Gary King
>
> : Gary King, King(a)Harvard.Edu http://GKing.Harvard.Edu :
> : Center for Basic Research Direct (617) 495-2027 :
> : in the Social Sciences Assistant (617) 495-9271 :
> : 34 Kirkland Street, Rm. 2 HU-MIT DC (617) 495-4734 :
> : Harvard U, Cambridge, MA 02138 eFax (617) 812-8581 :
>
> On Mon, 7 Jun 2004, Leonelo Bautista wrote:
>
> > I'm imputing values for missing blood lipids (roughly 20% out of
> 3000> observations) in a cross-sectional data set. Some of the
> imputed values are
> > not possible (for example, negative triglycerides levels). I'm
> not sure how
> > to handle these imputed values. Should I just ignore then and go
> ahead with
> > the analysis? Is it possible to impose restrictions on the model
> (using> Amelia) to make all triglyceride values positive?
> > Any suggestions will be appreciated.
> >
> > Leonelo E. Bautista, MD, DrPH
> > Assistant Professor
> > University of Wisconsin Medical School
> > Population Health Sciences
> > 610 Walnut Street, 703 WARF
> > Madison, WI 53726-2397
> > Phone: (608)265-6176
> > Fax: (608)263-2820
> >
> >
> >
> >
>
I'm imputing values for missing blood lipids (roughly 20% out of 3000
observations) in a cross-sectional data set. Some of the imputed values are
not possible (for example, negative triglycerides levels). I'm not sure how
to handle these imputed values. Should I just ignore then and go ahead with
the analysis? Is it possible to impose restrictions on the model (using
Amelia) to make all triglyceride values positive?
Any suggestions will be appreciated.
Leonelo E. Bautista, MD, DrPH
Assistant Professor
University of Wisconsin Medical School
Population Health Sciences
610 Walnut Street, 703 WARF
Madison, WI 53726-2397
Phone: (608)265-6176
Fax: (608)263-2820